Greenway Therapeutix CEO, Dr. Michael Milane presents at the 2019 Practical Symposium
Beaver Creek, CO, August 09, 2019 – Greenway Therapeutix, Inc., a Biopharmaceutical company dedicated to the research and development of medical grade cannabinoid therapeutics utilizing nanotechnology, was at the 2019 Practical Symposium in Beaver Creek, Colorado.
The company’s CEO, Dr. Michael Milane, presented on the potential for cannabinoid therapeutics in Dermatology. This was one of the first times times in US history, that human clinical data has been presented looking at the efficacy and safety results with the utilization of a natural medical grade CBD for specific skin conditions.
In addition to the medical historical content and legal background, Dr. Milane covered the science behind the endocannabinoid systems, specifics of cannabidiol (CBD) mechanisms of action, and potential clinical applications in skin disease. For the first time, data was released on several clinical observational studies and efficacy results for eczema, rosacea, pain, and itch.
Dr. Dan Siegel, a previous president of the Academy of Dermatology and a Board Certified Dermatologist from New York, indicated that the initial data for multiple conditions look very promising and merit further investigation in larger trials to follow.
About Greenway Therapeutix
Greenway Therapeutix is a medically focused Biopharmaceutical company created by doctors and scientists.
They are dedicated to the research and development of medical-grade cannabinoid therapeutic products, while utilizing cutting edge nanotechnology in their delivery. High-Potency Cannabidiol Therapeutic products are currently in clinical development and testing for the evaluation of multiple inflammatory skin conditions. The lead product, Canno™Cream, is a novel nano CBD cream designed to provide potential relief for chronic inflammatory skin conditions such as itch, eczema, psoriasis, rosacea, and pain.
For more information, visit www.greenwaytherapeutix.com.
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential, “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.